FDA endorses demand for new Cipher study

The FDA has come down on the side of one of its divisions and will require Canada's Cipher Pharmaceuticals to mount a new trial in order to substantiate the safety of CIP-Isotretinoin for severe acne. Cipher had appealed the decision of the FDA's Division of Dermatology and Dental Products, saying that researchers had addressed the clinical question. Cipher says it's now reviewing the FDA's position to see how to best proceed.

- here's the release on the FDA's decision

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.